Evotec (NASDAQ:EVO) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded Evotec from "hold" to "sell", adding pressure to the biotech stock.
• Despite the downgrade, other analysts remain more constructive: Evotec still has an overall Moderate Buy consensus, with an average price target of $7.00.
• Evotec shares were trading around $3.07 after a 0.7% gain, while recent earnings showed $0.05 EPS on $297.02 million in revenue and continued negative profitability metrics.

Evotec (NASDAQ:EVO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright assumed coverage on shares of Evotec in a research note on Wednesday, April 15th. They issued a "buy" rating and a $7.00 price target on the stock. Berenberg Bank assumed coverage on shares of Evotec in a research note on Tuesday, February 3rd. They issued a "buy" rating on the stock. Finally, Weiss Ratings upgraded shares of Evotec from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.00.

Evotec Trading Up 0.7%

Shares of Evotec stock opened at $3.07 on Friday. The firm's 50-day moving average is $2.85 and its 200 day moving average is $3.21. Evotec has a 1 year low of $2.31 and a 1 year high of $4.80. The company has a current ratio of 1.68, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.

Evotec (NASDAQ:EVO - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $297.02 million for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. As a group, equities analysts anticipate that Evotec will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evotec

Several hedge funds and other institutional investors have recently bought and sold shares of EVO. Bank of America Corp DE lifted its stake in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after acquiring an additional 9,289 shares during the period. XTX Topco Ltd bought a new position in Evotec during the 2nd quarter valued at about $66,000. Marshall Wace LLP bought a new position in Evotec during the 2nd quarter valued at about $169,000. BNP Paribas Financial Markets lifted its stake in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after acquiring an additional 4,600 shares during the period. Finally, Snowden Capital Advisors LLC bought a new position in Evotec during the 2nd quarter valued at about $122,000. Institutional investors own 5.81% of the company's stock.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Evotec AG NASDAQ: EVO and kept a $7.00 price target, citing a path to improving earnings over the next few years.
• Positive Sentiment: The firm lifted its Q4 2026 EPS estimate to $0.01 from a prior loss expectation, suggesting improving near-term profitability.
• Neutral Sentiment: The analyst maintained relatively constructive forecasts for FY2027-FY2029, but still expects only modest earnings, with some of those estimates slightly reduced. Article Title
• Negative Sentiment: Recent earnings coverage indicated Evotec reported a wider quarterly loss and missed revenue expectations, which could weigh on the stock.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.